title: Characteristics associated with maintenance of mean A1C<6.5% in people with dysglycemia in the ORIGIN trial.
abstract: OBJECTIVE
  To assess the success and baseline predictors of maintaining glycemic control for up to 5 years of therapy using basal insulin glargine or standard glycemic care in people with dysglycemia treated with zero or one oral glucose-lowering agents.
  
  
  METHODS
  Data from 12,537 participants in the Outcome Reduction with Initial Glargine Intervention (ORIGIN) trial were examined by baseline glycemic status (with or without type 2 diabetes) and by therapeutic approach (titrated insulin glargine or standard therapy) using an intention-to-treat analysis. Median values for fasting plasma glucose (FPG) and A1C and percentages with A1C<6.5% (48 mmol/mol) during randomized treatment were calculated. Factors independently associated with maintaining updated mean A1C<6.5% were analyzed with linear regression models.
  
  
  RESULTS
  Median A1C in the whole population was 6.4% at baseline; at 5 years, it was 6.2% with glargine treatment and 6.5% with standard care. Of those with diabetes at baseline, 60% using glargine and 45% using standard care had A1C<6.5% at 5 years. Lack of diabetes and lower baseline A1C were independently associated with 5-year mean A1C<6.5%. Maintaining mean A1C<6.5% was more likely with glargine (odds ratio [OR] 2.98 [95% CI 2.67-3.32], P<0.001) than standard care after adjustment for other independent predictors.
  
  
  CONCLUSIONS
  Systematic intervention with basal insulin glargine or standard care early in the natural history of dysglycemia can maintain glycemic control near baseline levels for at least 5 years, whether diabetes is present at baseline or not. Keeping mean A1C<6.5% is more likely in people with lower baseline A1C and with the glargine-based regimen.
authors: Corresponding author: Matthew C. Riddle, riddlem@ohsu.edu.
mesh_terms: D000368:Aged; D001786:Blood Glucose / Q000187:drug effects; D003924:Diabetes Mellitus, Type 2 / Q000097:blood / Q000188:drug therapy; D005260:Female; D006442:Glycated Hemoglobin / Q000378:metabolism; D006801:Humans; D007004:Hypoglycemic Agents / Q000627:therapeutic use*; D000069036:Insulin Glargine; D049528:Insulin, Long-Acting / Q000627:therapeutic use*; D008297:Male; D008875:Middle Aged; D016896:Treatment Outcome
chemical_list: D001786:Blood Glucose; D006442:Glycated Hemoglobin; D007004:Hypoglycemic Agents; D000069036:Insulin Glargine; D049528:Insulin, Long-Acting
references: Diabetes Care. 2012 Jan;35 Suppl 1:S64-71
references: 22187472
references: N Engl J Med. 2012 Jul 26;367(4):319-28
references: 22686416
references: N Engl J Med. 2008 Jun 12;358(24):2545-59
references: 18539917
references: Diabetes Care. 2004 Jul;27(7):1535-40
references: 15220224
references: JAMA. 1999 Feb 10;281(6):558-60
references: 10022113
references: Diabetes Care. 2009 Aug;32(8):1440-6
references: 19401445
references: N Engl J Med. 2012 Jul 26;367(4):309-18
references: 22686415
references: Q J Med. 1986 Jun;59(230):579-98
references: 3749450
references: Diabetologia. 2010 Dec;53(12):2509-17
references: 20711717
references: N Engl J Med. 2008 Jun 12;358(24):2560-72
references: 18539916
references: N Engl J Med. 2006 Dec 7;355(23):2427-43
references: 17145742
references: Diabetologia. 2012 Dec;55(12):3228-37
references: 22935962
references: Lancet. 1998 Sep 12;352(9131):837-53
references: 9742976
references: N Engl J Med. 2010 Jul 15;363(3):233-44
references: 20587587
references: Diabetes Care. 2010 Mar;33(3):501-6
references: 20040656
references: BMJ. 2010 Jan 08;340:b5444
references: 20061360
references: Lancet. 1998 Sep 12;352(9131):854-65
references: 9742977
references: Endocrinol Metab Clin North Am. 2012 Mar;41(1):41-56
references: 22575406
references: N Engl J Med. 2009 Jan 8;360(2):129-39
references: 19092145
references: Am Heart J. 2008 Jan;155(1):26-32, 32.e1-6
references: 18082485
references: Diabetes. 1995 Nov;44(11):1249-58
references: 7589820
references: BMJ. 2000 Aug 12;321(7258):405-12
references: 10938048
references: Lancet. 2010 Aug 7;376(9739):419-30
references: 20594588
references: Lancet. 2010 Jun 26;375(9733):2215-22
references: 20609967
references: Diabetes Care. 2012 Jan;35 Suppl 1:S11-63
references: 22187469
references: Endocr Pract. 2009 Sep-Oct;15(6):540-59
references: 19858063